Intervention research in psychosis: Issues related to the assessment of quality of life

Schizophrenia Bulletin

Volumn 26, Issue 3, 2000, Pages 557-564

  Awad, A G ^a   Voruganti, L N P ^a  

^a HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

Antipsychotics; Conceptual models; Psychosis; Quality of life; Research issues; Schizophrenia

Indexed keywords

ARTICLE; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SCHIZOPHRENIA;

EID: 0033851163     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033477     Document Type: Article

References (40)

1. Characterizing quality of life among patients with chronic mental illness: A critical examination of self-report methodology
2. Quality of life of schizophrenic patients on medications and implications for new drug trials
3. Quality of life issues in medicated schizophrenic patients
4. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life
5. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride
6. Neuroleptics and quality of life in schizophrenia
7. Cost-utility in schizophrenia
8. Quality of life and new antipsychotics in schizophrenia: Are patients better off?
9. Measuring quality of life in patients with schizophrenia
10. Preliminary validation of a conceptual model to assess quality of life in schizophrenia
11. The Sickness Impact Profile: Development and final version of the health status measure
12. Quality of life in cancer patients - A hypothesis
13. Subjective measures of well-being
14. Subjective quality of life: Clinical model for assessment of rehabilitation treatment in schizophrenia
15. The economic burden of schizophrenia
16. The Global Assessment Scale - A procedure for measuring overall severity of psychiatric disturbance
17. The Hillside Akathisia Scale: A new rating instrument for neuroleptic-induced akathisia
18. A critical appraisal of the quality of life measurements
19. What are the functional consequences of neurocognitive deficits in schizophrenia?
20. Pharmacoeconomics of antipsychotic drug therapy
21. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia
22. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures
23. A self-report scale predictive of drug compliance in schizophrenia: Reliability and discriminative ability
24. Significance of positive and negative syndromes in chronic schizophrenia
25. The well-being of chronic mental patients: Assessing their quality of life
26. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
27. Chronic mental patients: The quality of life issue
28. Quality of life in chronically mentally ill patients in day-treatment
29. Evaluations of quality of life of schizophrenic outpatients: A checklist
30. Subjective effects of neuroleptics predict compliance
31. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
32. Comparison of quality of life with standard of living in schizophrenic outpatients
33. Quality of life of seriously mentally ill persons in Mississippi
34. Subjective response as a predictor of outcome in pharmacotherapy
35. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effects profile and impact on quality of life
36. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability
37. Conceptualizing disease impact and treatment outcomes
38. The quality of life of people with schizophrenia in Boulder, Colorado, and Bologna, Italy
39. Reintegration to normal living as a proxy to quality of life
40. The measurement of social behaviour in psychiatric patients: An assessment of the reliability and validity of SBS schedule